

Agreements with U-Vet for Phase II Trial in Pet Dogs with Cancer finalised

- **PharmAust and U-Vet Werribee Animal Hospital (University of Melbourne) finalise Agreement to begin canine cancer treatment trials**

10 September 2019 – Perth, Australia: PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce finalisation of contractual arrangements for the Phase II canine cancer trial with the University of Melbourne’s U-Vet Werribee Animal Hospital.

Recruitment of canine patients will now commence at U-Vet to formally test monepantel (MPL) in the new palatable and high dose tablet form in pet owners’ dogs with treatment-naïve B cell lymphoma.

U-Vet is one of Australia’s leading veterinary hospitals. The trial will be overseen by Dr Claire Cannon, Head of Small Animal Medicine and Oncology at U-Vet and a specialist veterinary oncologist with extensive experience working at the University of Melbourne, the Universities of Minnesota and Tennessee and in private practice in Australia and the UK.

Dr Cannon will also oversee recruitment at other nominated sites within Australia, facilitating accelerated accrual rates, and enabling faster trial endpoint determination. Acceptance for these other sites to participate in the trial is currently being finalised with appropriate agreements. Multi-site involvement represents a step-by-step process and the Company looks forward to the other sites adding to the U-Vet site once formalities are finalised.

PharmAust’s Chief Scientific Officer Dr Richard Mollard said: “PharmAust is very pleased to be working with Dr Cannon and her team at U-Vet and the University of Melbourne. PharmAust is looking forward to sharing the data generated from the trial at U-Vet and other sites when they become available.”

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com



About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. PAA's subsidiary, Epicchem, is a successful contract medicinal chemistry company that is forecasting \$4.2m revenues in FY2019/20.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs; was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials.

About U-Vet:

The University of Melbourne's U-Vet Werribee Animal Hospital is one of Australia's leading veterinary hospital facilities, based in Werribee. U-Vet offers complete animal care to the public including general practice (primary and preventative care, exotic pet care), a suite of specialist referral services, specialist support services, 24-hour emergency care and specialist referral equine services. The hospital also trains the next generation of veterinarians and veterinary specialists with the assistance of its academic staff, who are world leaders in clinical excellence and research.

About University of Melbourne:

Established in 1853, the University of Melbourne is a public-spirited institution that makes distinctive contributions to society in research, learning and teaching and engagement. It's consistently ranked among the leading universities in the world, with international rankings of world universities placing it as number 1 in Australia and number 32 in the world (Times Higher Education World University Rankings 2017-2018). The University's distinctive Melbourne experience helps graduates become well-rounded, thoughtful and skilled professionals – making a positive impact across the globe. Its research helps solve social, economic and environmental challenges the world is facing today and into the future.